BioNTech SE (BNTX) financial statements

Healthcare · Biotechnology · Market cap $24.5B

BioNTech SE reported revenue of 2.9B EUR in fiscal 2025, up 61.6% a year over 8 years.

Net income was -1.1B EUR and the operating margin -49.0%, against -99.5% in 2017.

Free cash flow was 281M EUR.

The diluted share count rose 45% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (EUR).

-505101520201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, in EUR, from BioNTech SE's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Revenue62M EUR128M EUR109M EUR482M EUR19.0B EUR17.3B EUR3.8B EUR2.8B EUR2.9B EUR
Cost of revenue9M EUR14M EUR17M EUR59M EUR2.9B EUR3.0B EUR600M EUR541M EUR642M EUR
Gross profit52M EUR114M EUR91M EUR423M EUR16.1B EUR14.3B EUR3.2B EUR2.2B EUR2.2B EUR
Research and development85M EUR143M EUR226M EUR645M EUR949M EUR1.5B EUR1.8B EUR2.3B EUR2.1B EUR
Selling, general and admin24M EUR26M EUR46M EUR94M EUR277M EUR482M EUR495M EUR531M EUR514M EUR
Operating income-61M EUR-54M EUR-182M EUR-82M EUR15.3B EUR12.6B EUR690M EUR-1.3B EUR-1.4B EUR
Interest expense26M EUR48,000 EUR2M EUR65M EUR305M EUR19M EUR8M EUR17M EUR14M EUR
Pre-tax income-86M EUR-48M EUR-179M EUR-146M EUR15.0B EUR13.0B EUR1.2B EUR-678M EUR-1.1B EUR
Income tax45,000 EUR600,000 EUR-200,000 EUR-161M EUR4.8B EUR3.5B EUR256M EUR-12M EUR85M EUR
Net income-86M EUR-48M EUR-179M EUR15M EUR10.3B EUR9.4B EUR930M EUR-665M EUR-1.1B EUR
EPS (diluted)——-0.85 EUR0.06 EUR39.63 EUR37.77 EUR3.83 EUR-2.77 EUR-4.70 EUR
Diluted shares167M191M212M248M260M250M243M240M242M
Gross margin84.9%89.3%84.0%87.7%84.7%82.7%84.3%80.3%77.6%
Operating margin-99.5%-42.2%-167.1%-17.1%80.5%73.0%18.1%-47.8%-49.0%
Net margin-139.1%-37.6%-164.9%3.2%54.2%54.5%24.4%-24.2%-39.6%

Balance sheet

Fiscal years, in EUR, from BioNTech SE's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Cash and short-term investments172M EUR412M EUR519M EUR1.2B EUR1.7B EUR13.9B EUR11.7B EUR9.8B EUR7.7B EUR
Receivables—19M EUR12M EUR166M EUR12.4B EUR7.1B EUR2.2B EUR1.5B EUR924M EUR
Inventory—6M EUR12M EUR64M EUR502M EUR440M EUR358M EUR283M EUR111M EUR
Total current assets—449M EUR560M EUR1.7B EUR15.1B EUR21.9B EUR19.5B EUR18.8B EUR16.1B EUR
Property, plant and equipment50M EUR66M EUR93M EUR227M EUR322M EUR609M EUR757M EUR935M EUR1.1B EUR
Goodwill——3M EUR54M EUR58M EUR61M EUR362M EUR381M EUR368M EUR
Total assets—653M EUR798M EUR2.3B EUR15.8B EUR23.3B EUR23.0B EUR22.5B EUR22.0B EUR
Total current liabilities—126M EUR138M EUR606M EUR3.5B EUR3.0B EUR2.1B EUR2.5B EUR2.1B EUR
Long-term debt——69M EUR231M EUR172M EUR————
Total liabilities—386M EUR304M EUR947M EUR3.9B EUR3.2B EUR2.8B EUR3.1B EUR2.8B EUR
Shareholders' equity-48M EUR266M EUR493M EUR1.4B EUR11.9B EUR20.1B EUR20.2B EUR19.4B EUR19.2B EUR
Net debt-172M EUR-412M EUR-445M EUR-970M EUR-1.4B EUR-13.9B EUR-11.7B EUR-9.8B EUR-7.7B EUR

Cash flow

Fiscal years, in EUR, from BioNTech SE's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Operating cash flow-53M EUR-59M EUR-198M EUR-14M EUR890M EUR13.6B EUR5.4B EUR208M EUR456M EUR
Capital spending58M EUR67M EUR71M EUR66M EUR128M EUR329M EUR249M EUR286M EUR175M EUR
Free cash flow-110M EUR-126M EUR-270M EUR-80M EUR762M EUR13.2B EUR5.1B EUR-79M EUR281M EUR
Stock-based compensation6M EUR8M EUR30M EUR32M EUR94M EUR109M EUR51M EUR101M EUR106M EUR
Dividends paid———0 EUR0 EUR484M EUR0 EUR0 EUR—
Net borrowing—6M EUR11M EUR154M EUR-53M EUR-18M EUR200,000 EUR-2M EUR-11M EUR
Free cash flow margin-179.1%-98.8%-248.2%-16.5%4.0%76.5%134.1%-2.9%9.8%
Dividends per share—————1.94 EUR———
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BNTX.
Open BNTX in Investingly

Questions

What was BioNTech SE's revenue in 2025?

2.9B EUR in fiscal 2025, from its 10-K filing.

How much free cash flow does BioNTech SE generate?

281M EUR in fiscal 2025 (operating cash flow minus capital spending).

From BioNTech SE's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.